Opthea (OPT) Competitors $3.41 +0.23 (+7.23%) As of 09/18/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPT vs. OCUL, BLTE, IDYA, AGIO, ANIP, RXRX, TVTX, BEAM, TARS, and IRONShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Ocular Therapeutix (OCUL), Belite Bio (BLTE), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), ANI Pharmaceuticals (ANIP), Recursion Pharmaceuticals (RXRX), Travere Therapeutics (TVTX), Beam Therapeutics (BEAM), Tarsus Pharmaceuticals (TARS), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Its Competitors Ocular Therapeutix Belite Bio IDEAYA Biosciences Agios Pharmaceuticals ANI Pharmaceuticals Recursion Pharmaceuticals Travere Therapeutics Beam Therapeutics Tarsus Pharmaceuticals Disc Medicine Ocular Therapeutix (NASDAQ:OCUL) and Opthea (NASDAQ:OPT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Does the media favor OCUL or OPT? In the previous week, Ocular Therapeutix had 6 more articles in the media than Opthea. MarketBeat recorded 6 mentions for Ocular Therapeutix and 0 mentions for Opthea. Ocular Therapeutix's average media sentiment score of 0.81 beat Opthea's score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Overall Sentiment Ocular Therapeutix Positive Opthea Neutral Do insiders and institutionals hold more shares of OCUL or OPT? 59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 3.2% of Opthea shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, OCUL or OPT? Opthea has lower revenue, but higher earnings than Ocular Therapeutix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M33.04-$193.51M-$1.28-9.45Opthea$87.67K5,986.77-$162.79MN/AN/A Do analysts prefer OCUL or OPT? Ocular Therapeutix presently has a consensus price target of $17.83, suggesting a potential upside of 47.38%. Opthea has a consensus price target of $1.33, suggesting a potential downside of 60.90%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17 Is OCUL or OPT more profitable? Opthea has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Opthea's return on equity of 0.00% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-382.51% -71.92% -49.36% Opthea N/A N/A N/A Which has more risk and volatility, OCUL or OPT? Ocular Therapeutix has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Opthea has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. SummaryOcular Therapeutix beats Opthea on 8 of the 15 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.84M$3.12B$5.75B$10.42BDividend YieldN/A2.37%5.74%4.63%P/E RatioN/A20.6576.5526.74Price / Sales5,986.77385.03494.58162.18Price / CashN/A45.3237.1760.63Price / Book-2.609.6613.726.40Net Income-$162.79M-$53.02M$3.29B$271.71M7 Day PerformanceN/A1.09%1.03%2.85%1 Month PerformanceN/A7.93%6.32%9.64%1 Year Performance-11.66%10.48%81.16%31.62% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea0.1637 of 5 stars$3.41+7.2%$1.33-60.9%-2.6%$524.84M$87.67K0.008Positive NewsGap UpOCULOcular Therapeutix3.9072 of 5 stars$12.54-2.1%$17.83+42.2%+40.4%$2.23B$63.72M-9.80230Positive NewsGap UpBLTEBelite Bio2.8599 of 5 stars$66.80-3.9%$96.00+43.7%+51.6%$2.21BN/A-43.1010News CoverageAnalyst UpgradeAnalyst RevisionHigh Trading VolumeIDYAIDEAYA Biosciences3.9988 of 5 stars$24.53-0.3%$42.85+74.7%-24.5%$2.16B$7M-6.4780Analyst ForecastAGIOAgios Pharmaceuticals4.3155 of 5 stars$36.30-1.3%$56.00+54.3%-16.7%$2.14B$36.50M3.30390ANIPANI Pharmaceuticals4.0495 of 5 stars$98.81+1.1%$88.25-10.7%+59.7%$2.12B$614.38M-128.32600Analyst ForecastAnalyst RevisionRXRXRecursion Pharmaceuticals2.1658 of 5 stars$4.77-1.2%$7.25+52.0%-28.7%$2.10B$58.84M-2.68400TVTXTravere Therapeutics3.0146 of 5 stars$23.01-2.0%$34.20+48.6%+68.6%$2.09B$233.18M-11.28460Analyst ForecastBEAMBeam Therapeutics3.1801 of 5 stars$21.28+3.3%$46.40+118.0%-1.6%$2.08B$60.27M-4.73510TARSTarsus Pharmaceuticals2.3552 of 5 stars$49.59+0.5%$66.67+34.4%+66.0%$2.08B$182.95M-21.2850Positive NewsIRONDisc Medicine3.0734 of 5 stars$59.90+0.1%$98.30+64.1%+31.4%$2.08BN/A-13.4030Positive News Related Companies and Tools Related Companies OCUL Alternatives BLTE Alternatives IDYA Alternatives AGIO Alternatives ANIP Alternatives RXRX Alternatives TVTX Alternatives BEAM Alternatives TARS Alternatives IRON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPT) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPT Stock Alerts